Aprea TherapeuticsEPS of -$4.34

Aug. 11, 2022 5:36 PM ETAprea Therapeutics, Inc. (APRE)By: Deepa Sarvaiya, SA News Editor
  • Aprea Therapeutics press release (NASDAQ:APRE): Q2 EPS of -$4.34 may not be comparable to consensus of -$0.31.
  •  As of June 30, 2022, the Company had $39.1 million of cash and cash equivalents compared to $53.1 million of cash and cash equivalents as of December 31, 2021. The Company believes its cash and cash equivalents as of June 30, 2022 will be sufficient to meet its current projected operating requirements through the end of 2023.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.